Simulations Plus, Inc. (NASDAQ:SLP) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET
Company Participants
John Wilfong - Investor Relations, Financial Profiles
Shawn O'Connor - Chief Executive Officer
Will Frederick - Chief Financial Officer
Conference Call Participants
Matt Hewitt - Craig-Hallum
David Larsen - BTIG
Yuan Zhi - B. Riley
Francois Brisebois - Oppenheimer
Operator
Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, John Wilfong from Financial Profiles. Thank you. Mr. Wilfong, you may begin.
John Wilfong
Good afternoon, everyone. Welcome to the Simulations Plus third quarter fiscal 2023 financial results conference call.
With me today are Shawn O'Connor, Chief Executive Officer, and Will Frederick, our Chief Financial Officer of Simulations Plus.
Please note that we have -- we updated our quarterly earnings presentation, which will serve as a supplement to today's prepared remarks. You can access the presentation on our Investor Relations page at www.simulations-plus.com. After management's commentary, we will open the call for questions.
As a reminder, information discussed today may include forward-looking statements that involve risks and uncertainties. Words like believe, expect and anticipate refer to our best estimates as of this call. There are no -- there can be no assurances that these will actually take place. So our actual future results could differ significantly from these statements. Further information on the company's risk factors is contained in the company's quarterly and annual reports and filed with the Securities and Exchange Commission.
With that said, I will turn over the call to Shawn O'Connor. Shawn?
Shawn O'Connor
Thank you, John. Good afternoon, everyone, and thank you for joining us today to discuss our third quarter 2023 results.
To start off, I am pleased with our team's successful acquisition of Immunetrics, a well-respected modeling and simulation company. This acquisition is highly complementary to our core strength and expertise in quantitative systems pharmacology, or QSP. With Immunetrics, we can rapidly expand into the fast-growing therapeutic areas of oncology, immunology and autoimmune diseases. We are very excited to welcome the Immunetrics team that brings proven QSP technology, a strong reputation in the market and incredible scientific talent to Simulations Plus. By joining forces, we believe we can establish a leading position in these rapidly growing therapeutic areas.